Diabetic Retinopathy Market Expected to be Valued at $10.11 Billion by 2022 | Million Insights

Wednesday, April 11, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

FELTON, California, April 11, 2018 /PRNewswire/ --

The global Diabetic Retinopathy Market was valued at

USD 5,934.1 million in 2014 and is expected to reach USD 10.11 billion by 2022, with a CAGR of 6.8%. Diabetes is a constant disorder linked with defects in the discharge of insulin from the
hyperglycemia or pancreas related to insulin resistance which eventually directs to long term multi-organ difficulties of kidneys, eye, heart, nerves and blood vessels. The mainly severe and common sight intimidating impediment of diabetes is DR (Diabetic Retinopathy) by some form of Diabetic Retinopathy, it directs to damage of the blood vessels near the retina of an eye. DR is described as an eye turmoil that harms the blood vessels of the retina. The retina is the light susceptible inner exterior of the eye which takes action as a screen for the creation of an image. Long-term diabetes influences the retina as a soaring blood glucose stage can worsen and harm the miniature blood vessels in the eye (retina).

Diabetic Retinopathy is generally classified into either proliferative retinopathy or non-proliferative DR. Cure for DR is dependent relatively on the phase of the ailment and is focused on trying to stop or slow the succession of the disease. Currently three types of cure exist for Diabetic Retinopathy which is anti-VEGF drugs into the eye or injection of corticosteroids, laser surgery and vitrectomy. Advancements in knowledge have led to the modernization of new goods that offer rapid and secure methods to cure diabetic retinopathy. Augmented use of vitrectomy in the healing of retinal impassiveness is one such trend.

The increase in diabetes tolerant, great inhabitants of baby boomers, and shifting lifestyle in budding countries are some of the leading factors expected to drive diabetic retinopathy market over the forecast period. Additionally, the amplified health awareness and growing disposable income in budding countries have enlarged the superior healthcare services, affordability; which in turns is driving the industry of diabetic retinopathy. The growing awareness in the direction of the cure of diabetic retinopathy and progression of patient monitoring by the electronic medical record are some of current market trend in the diabetic retinopathy industry. The treatment process of diabetic retinopathy depends on a variety of stages of diabetic retinopathy. The increasing market for diabetic retinopathy can be accredited to increasing geriatric population size.

Browse 80 page research report with TOC on "Global Diabetic Retinopathy Market" at: https://www.millioninsights.com/industry-reports/diabetic-retinopathy-market 

Additionally, up gradation of healthcare infrastructure in the length of the increasing demand for early on detection systems are some of the soaring impact drivers for the DR industry. Also, the medical pipeline for Diabetic Retinopathy seems full of assurance by lots of drug beneath umbrella specially directing towards diabetic retinopathy amongst the diabetic patients. Moreover, a shortage of skilled ophthalmologist coupled with deprived primary infrastructure and shortage in a requirement of insurance facilities are expected to pose the challenge for the growth of global diabetic retinopathy industry.

On the basis disease type, the global diabetic retinopathy industry can be broadly categorized as proliferative retinopathy and non-proliferative diabetic retinopathy. On the basis of the different treatment techniques, the global diabetic retinopathy industry can be generally categorized as corticosteroids injection, Laser surgery, and anti-VEGF drugs. On the basis of different drug use in the worldwide diabetic retinopathy industry, the market can be bifurcated as Anti-Angiogenic, ocriplasmin, BI-30089, Squalamine Lactate, Proteoglycan, OC-10X, Lycium, ATL-1103 and STP-601.On the basis of a geographical region, the market can be segregated into Asia Pacific, North America, Europe and Rest of world. North America is expected to be the major market for diabetic retinopathy over the forecast period. The industry supremacy of North America is accredited to the soaring obesity rates and huge diabetic patients in this area. Furthermore, the helpful government proposal is also expected to be one of the important drivers of the industry in this area over the forecast period.

Europe is expected to be the second major market of diabetic retinopathy over the forecast period owing to the huge inhabitants of baby boomers in Europe is the most dominating growth factor for the diabetic retinopathy industry in this region over the forecast period. Asia Pacific is expected to demonstrate the highest expansion over the forecast period. The worthwhile augmentation of the diabetic retinopathy industry in Asia Pacific is accredited to the presence of a huge number of diabetic patients in China and India. Furthermore, increasing health consciousness coupled with growing expenditure on healthcare services is also propelling the diabetic retinopathy industry in this area. Beneath Rest of the World, sector Brazil is the biggest opportunity of diabetic retinopathy.

Some of the key players present in the market are Abbott Laboratories Inc, Hoffmann-La Roche Ltd, Bayer AG, Bayer AG, Novartis AG, Ampio Pharmaceuticals Inc, Alimera Science Inc, Regeneron Pharmaceutical Inc, and Pfizer Inc. Strategic acquisitions, new product launches, collaborations, agreements, mergers & acquisitions and joint ventures are some of the main things that are being done by the key players present in the market.

Browse reports of similar category available with Million Insights: 

  • Anesthesia CO2 Absorbent Market 
  • Chemiluminiscence Imaging Market 
  • Electroceuticals/Bioelectric Medicine Market 
  • Cardiac Rhythm Management Market 

Global Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2012 - 2022) 

    • Proliferative

    • Non proliferative

Global Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2012 - 2022) 

    • Anti VEGF

    • Intraocular steroid injection

    • Laser surgery

    • Vitrectomy

Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2012 - 2022) 

    • North America

        • U.S.

        • Canada

    • Europe

        • Germany

        • UK

        • Rest of Europe

    • Asia Pacific

        • Japan

        • China

        • Rest of Asia Pacific

    • Latin America

        • Brazil

        • Rest of Latin America

About Million Insights: 

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place, that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact: Ryan Manuel Research Support Specialist, USA Million Insights Phone: +1-408-610-2300 Toll Free: 1-866-831-4085 Email: sales@millioninsights.com

Web: https://www.millioninsights.com/

SOURCE Million Insights



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store